Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer

Wei-Ying Diao; Cheng-Long Ding; Bo-Yang Yuan; Zan Li; Na Sun; Jia-Bin Huang

doi:10.2147/IJGM.S328908

Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer

Int J Gen Med. 2021 Dec 1:14:9153-9161. doi: 10.2147/IJGM.S328908. eCollection 2021.

Authors

Wei-Ying Diao^#¹, Cheng-Long Ding^#¹, Bo-Yang Yuan², Zan Li³, Na Sun⁴, Jia-Bin Huang⁵

Affiliations

¹ Department of Pathology, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People's Republic of China.
² Department of Acupuncture and Moxibustion, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People's Republic of China.
³ Department of Analytical Chemistry Teaching and Research, Jiamusi University, Jiamusi City, Heilongjiang Province, 154002, People's Republic of China.
⁴ Graduate Department, Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People's Republic of China.
⁵ Department of Geratology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People's Republic of China.

^# Contributed equally.

Abstract

Introduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients.

Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to January 2018 were retrospectively analyzed. The clinicopathological information, CT signs, clinical efficacy and long-term prognosis were collected and compared.

Results: A total of 249 NSCLC patients underwent HER2 gene testing, 21 of them (8.43%) complied with HER2 alterations [HER2 (+)], and there were significant differences in tumor stages among patients with different HER2 phenotypes (P<0.05). Among 21 NSCLC patients with HER2 (+), HER2 gene mutation was found in 17 patients (81%), and HER2 gene amplification in 4 patients (19%). Among the HER2 mutations, 12 cases (57%) were 20 exon mutations, and 5 cases (19%) were other mutations. Analysis of CT signs showed that border lobulation/burr, necrosis sign and pleural depression were correlated with HER2 gene mutation (P<0.05). The incidence of EGRF mutation in HER (+) patients was significantly lower than that in HER (-) patients (P<0.05), but there was no significant difference in the incidence of ALK gene mutation among different HER phenotypes (P>0.05). The disease control rate of HER2 (+) patients was significantly lower than that of HER2 (-) patients, and the 12-month progression-free survival rate and survival rate of HER2 (+) patients were significantly higher than those of HER2 (-) patients (P<0.05). There was no significant difference in the incidence of ADR among HER2 patients with different phenotypes, but the incidence of ADR (adverse drug reaction) in HER2 (+) patients with Grade 3 or 4 was significantly higher than that in the control group (P<0.05).

Discussion: The incidence of HER2 gene mutations in NSCLC patients is relatively low, but it is far commoner in patients with stage IIIB~IV, among which exon 20 mutations are the most prevalent. In CT signs, the lesion lobulated sign/spiculated sign, necrosis signs, and pleural depression signs are related to HER2 gene mutations. In addition, HER2 gene mutations play a crucial role in the clinical prognosis and treatment safety of patients.

Keywords: CT signs; HER2 genotype; afatinib; non-small cell lung cancer.

Grants and funding

This work was supported by the basic research project of the Heilongjiang Provincial Education Department (grant number: 2020-KYYWF-0289).